tirzepatide journal A head-to-head study found that patients on (Zepbound/Mounjaro) lost about 20% of their body weight, compared to 14% for those on semaglutide (Ozempic/Wegovy), though the study was funded Tirzepatide vs semaglutide in real-world

Data availability The single-nucleus RNA-sequencing data (raw FASTQ files and processed count matrices) generated in this study from mouse hippocampus and dorsal vagal complex have been deposited in the ArrayExpress database at EMBL-EBI under accession code E-MTAB-16829

Increased Cardiovascular Risk : Psoriasis and obesity are associated with a higher risk of heart disease, creating a dangerous combination

weight management for specific formulations like Saxenda and Wegovy) Healthcare professionals should remain vigilant for signs of pancreatitis, which is listed as a known adverse effect in the Summary of Product Characteristics (SmPC) for all GLP-1 agents There is no official link established between GLP-1 therapy and pancreatic cancer based on current evidence NICE guidance for type 2 diabetes management (NG28) continues to recommend GLP-1 receptor agonists as appropriate treatment options when specific criteria are met

If you're ready to explore how Zepbound (tirzepatide) can fit into your wellness journey, check out our Plans & Pricing to get started today or Book a Free Introduction Call with our provider.